Webster Bank N. A. Has $1.21 Million Position in Abbott Laboratories (NYSE:ABT)

Webster Bank N. A. increased its position in Abbott Laboratories (NYSE:ABTFree Report) by 9.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,993 shares of the healthcare product maker’s stock after buying an additional 927 shares during the period. Webster Bank N. A.’s holdings in Abbott Laboratories were worth $1,210,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Zevenbergen Capital Investments LLC grew its holdings in Abbott Laboratories by 0.6% during the third quarter. Zevenbergen Capital Investments LLC now owns 21,419 shares of the healthcare product maker’s stock valued at $2,074,000 after purchasing an additional 130 shares during the last quarter. Rockland Trust Co. grew its holdings in Abbott Laboratories by 1.5% during the third quarter. Rockland Trust Co. now owns 91,868 shares of the healthcare product maker’s stock valued at $8,897,000 after purchasing an additional 1,343 shares during the last quarter. VisionPoint Advisory Group LLC grew its holdings in Abbott Laboratories by 7.4% during the third quarter. VisionPoint Advisory Group LLC now owns 3,106 shares of the healthcare product maker’s stock valued at $301,000 after purchasing an additional 215 shares during the last quarter. Gradient Investments LLC grew its holdings in Abbott Laboratories by 4.7% during the fourth quarter. Gradient Investments LLC now owns 257,508 shares of the healthcare product maker’s stock valued at $28,344,000 after purchasing an additional 11,508 shares during the last quarter. Finally, Boston Partners grew its holdings in Abbott Laboratories by 634.6% during the third quarter. Boston Partners now owns 29,758 shares of the healthcare product maker’s stock valued at $2,882,000 after purchasing an additional 25,707 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 0.6 %

Shares of ABT stock opened at $111.31 on Thursday. The stock has a market cap of $193.14 billion, a P/E ratio of 34.14, a price-to-earnings-growth ratio of 2.70 and a beta of 0.74. The stock has a fifty day moving average price of $115.03 and a 200 day moving average price of $106.77. Abbott Laboratories has a one year low of $89.67 and a one year high of $121.64. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.64 and a quick ratio of 1.16.

Abbott Laboratories (NYSE:ABTGet Free Report) last issued its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $1.19 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.19. The company had revenue of $10.24 billion during the quarter, compared to analysts’ expectations of $10.19 billion. Abbott Laboratories had a return on equity of 20.65% and a net margin of 14.27%. The business’s revenue was up 1.5% on a year-over-year basis. During the same period last year, the business earned $1.03 earnings per share. Analysts predict that Abbott Laboratories will post 4.62 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be issued a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, April 12th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 1.98%. Abbott Laboratories’s payout ratio is presently 67.48%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ABT shares. Raymond James increased their price objective on Abbott Laboratories from $124.00 to $127.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Wells Fargo & Company increased their price objective on Abbott Laboratories from $116.00 to $121.00 and gave the company an “overweight” rating in a research report on Wednesday, December 13th. Barclays increased their price objective on Abbott Laboratories from $133.00 to $141.00 and gave the company an “overweight” rating in a research report on Friday, January 26th. Citigroup increased their price objective on Abbott Laboratories from $126.00 to $128.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, TheStreet raised Abbott Laboratories from a “c+” rating to a “b-” rating in a research report on Thursday, December 21st. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $121.92.

Get Our Latest Research Report on Abbott Laboratories

Insider Activity

In other news, EVP Andrea F. Wainer sold 42,500 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $112.50, for a total value of $4,781,250.00. Following the completion of the sale, the executive vice president now directly owns 65,027 shares in the company, valued at $7,315,537.50. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total value of $1,500,000.00. Following the completion of the sale, the executive vice president now directly owns 78,704 shares in the company, valued at $9,444,480. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Andrea F. Wainer sold 42,500 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $112.50, for a total value of $4,781,250.00. Following the completion of the sale, the executive vice president now owns 65,027 shares of the company’s stock, valued at $7,315,537.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,435 shares of company stock worth $6,451,298. 0.47% of the stock is owned by corporate insiders.

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Recommended Stories

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTFree Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.